473930-22-2
473930-22-2
Chemical Structure
SM-276001
- CAS No.: 473930-22-2
- Formula:C16H21N7O
- Molecular Weight:327.38
IUPAC Name: 6-amino-2-(butylamino)-9-((6-methylpyridin-3-yl)methyl)-7,9-dihydro-8H-purin-8-one
InChIKey: UEIOLEMXCBOQAX-UHFFFAOYSA-N
SMILES: NC1=C2C(N(C(N2)=O)CC3=CN=C(C=C3)C)=NC(NCCCC)=N1
Biological Activity: SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SM-276001 | 99.70% | SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Isobe Y, et al. Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem. 2006 Mar 23;49(6):2088-95. [Content Brief]
- [2]. Koga-Yamakawa E, et al. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer. 2013 Feb 1;132(3):580-90. [Content Brief]
